International multicenter, multiplatform study to validate Taipan snake venom time as a lupus anticoagulant screening test with ecarin time as the confirmatory test: communication from the ISTH SSC subcommittee on Lupus Anticoagulant/Antiphospholipid antibodies

Article


Moore, G., Jones, P., Platton, S., Hussain, N., White, D., Thomas, W., Rigano, J., Pouplard, C., Gray, E. and Devreese, K. 2021. International multicenter, multiplatform study to validate Taipan snake venom time as a lupus anticoagulant screening test with ecarin time as the confirmatory test: communication from the ISTH SSC subcommittee on Lupus Anticoagulant/Antiphospholipid antibodies. Journal of Thrombosis and Haemostasis. 19 (12), pp. 3177-3192. https://doi.org/10.1111/jth.15438
TypeArticle
TitleInternational multicenter, multiplatform study to validate Taipan snake venom time as a lupus anticoagulant screening test with ecarin time as the confirmatory test: communication from the ISTH SSC subcommittee on Lupus Anticoagulant/Antiphospholipid antibodies
AuthorsMoore, G., Jones, P., Platton, S., Hussain, N., White, D., Thomas, W., Rigano, J., Pouplard, C., Gray, E. and Devreese, K.
Abstract

Background
Lupus anticoagulant (LA) assays are compromised in anticoagulated patients, and existing strategies to overcome the interferences have limitations. The prothrombin-activating Taipan snake venom time (TSVT) screening test and ecarin time (ET) confirmatory test are innately insensitive to vitamin K antagonists (VKA) and direct factor Xa inhibitors (DFXaI).
Objectives
Validate standardised TSVT/ET reagents for LA detection, in a multi-centre, multi-platform study.
Patients/Methods
Six centres from four countries analysed samples with TSVT/ET from 81 non-anticoagulated patients with LA, patients with established antiphospholipid syndrome (APS) and proven persistent LA who were either not anticoagulated (n=120) or were anticoagulated with VKAs (n=180) or DFXaIs (n=71). Additionally, 339 non-anticoagulated LA-negative patients, and 575 anticoagulated non-APS patients (172 VKA, 403 DFXaI) were tested. Anticoagulant spiking experiments were performed and 112 samples containing potential interferences (i.e. direct thrombin inhibitors) were tested. Results were evaluated against locally derived cut-offs. Imprecision was evaluated.
Results
Cut-offs were remarkably similar despite use of different analysers and donor populations. Cut-offs for TSVT ratio, ET ratio, percent correction and normalised TSVT ratio/ET ratio ranged between 1.08-1.10, 1.09-1.12, 9.3%-14.8% and 1.10-1.15 respectively. Coefficients of variation for TSVT and ET ratios were ≤5.0%. TSVT/ET exhibited sensitivity, specificity, negative and positive predictive values of 78.2%/95.0%/86.3%/91.5% respectively with established APS as the LA-positive population, and 86.9%/95.0%/76.8%/97.4% respectively with triple-positive APS. Interference was seen with direct thrombin inhibitors, unfractionated heparin and low molecular weight heparins, but not VKAs or DFXaIs.
Conclusions
TSVT/ET are validated for LA detection in non-anticoagulated patients and those on VKAs or DFXaIs.

KeywordsHematology
PublisherWiley
JournalJournal of Thrombosis and Haemostasis
ISSN1538-7933
Electronic1538-7836
Publication dates
Online10 Oct 2021
PrintDec 2021
Publication process dates
Submitted11 May 2021
Accepted28 Jun 2021
Deposited12 Jul 2021
Output statusPublished
Accepted author manuscript
File Access Level
Open
Copyright Statement

This is the peer reviewed version of the following article: Moore, GW, Jones, PO, Platton, S, et al. International multicenter, multiplatform study to validate Taipan snake venom time as a lupus anticoagulant screening test with ecarin time as the confirmatory test: Communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies. J Thromb Haemost. 2021; 19: 3177– 3192, which has been published in final form at https://doi.org/10.1111/jth.15438. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. This article may not be enhanced, enriched or otherwise transformed into a derivative work, without express permission from Wiley or by statutory rights under applicable legislation. Copyright notices must not be removed, obscured or modified. The article must be linked to Wiley’s version of record on Wiley Online Library and any embedding, framing or otherwise making available the article or pages thereof by third parties from platforms, services and websites other than Wiley Online Library must be prohibited

Web address (URL)https://onlinelibrary.wiley.com/doi/10.1111/jth.15438
https://www.sciencedirect.com/science/article/pii/S1538783622005323
Digital Object Identifier (DOI)https://doi.org/10.1111/jth.15438
LanguageEnglish
Permalink -

https://repository.mdx.ac.uk/item/896v4

Download files


Accepted author manuscript
jth.15438.pdf
File access level: Open

  • 124
    total views
  • 90
    total downloads
  • 2
    views this month
  • 0
    downloads this month

Export as

Related outputs

Diagnosing thrombophilia: the case for genetic or functional testing?
Favaloro, E.J., Moore, G.W. and Pasalic, L. 2025. Diagnosing thrombophilia: the case for genetic or functional testing? Expert Review of Molecular Diagnostics. 25 (12), pp. 841-846. https://doi.org/10.1080/14737159.2025.2588621
Survey on current practice in thrombophilia testing: from phenotype to genotype. Communication from the SSC of the ISTH
Van Laer, C., Moore, G.W., Majumder, R., Corral, J., Freson, K., Ignjatovic, V. and Orlando, C. 2025. Survey on current practice in thrombophilia testing: from phenotype to genotype. Communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2025.10.032
International Council for Standardization in Haematology (ICSH) recommendations for the performance and interpretation of activated partial thromboplastin time and prothrombin time mixing tests
Adcock, D.M., Moore, G., Kershaw, G.W., Montalvao, S. and Gosselin, R. 2024. International Council for Standardization in Haematology (ICSH) recommendations for the performance and interpretation of activated partial thromboplastin time and prothrombin time mixing tests. International Journal of Laboratory Hematology. 46 (5), pp. 777-788. https://doi.org/10.1111/ijlh.14344
International Council for Standardization in Haematology field study evaluating optimal interpretation methods for activated partial thromboplastin time and prothrombin time mixing studies
Gosselin, R.C., Moore, G.W., Kershaw, G.W., Montalvão, S. and Adcock, D.M. 2023. International Council for Standardization in Haematology field study evaluating optimal interpretation methods for activated partial thromboplastin time and prothrombin time mixing studies. Archives of Pathology & Laboratory Medicine. 148 (8), pp. 880-889. https://doi.org/10.5858/arpa.2023-0030-oa
Analytical dilemmas in lupus anticoagulant detection
Moore, G. 2023. Analytical dilemmas in lupus anticoagulant detection. Exploration of Immunology. 3, pp. 300-324. https://doi.org/10.37349/ei.2023.00104
ADAMTS13 activity measurement by ELISA and fluorescence resonance energy transfer assay
Moore, G., Llusa, M., Griffiths, M. and Binder, N. 2023. ADAMTS13 activity measurement by ELISA and fluorescence resonance energy transfer assay. in: Favaloro, E. and Gosselin, R. (ed.) Hemostasis and Thrombosis: Methods and Protocols New York, NY Humana.
ADAMTS13 activity: Screening test protocol
Moore, G., Griffiths, M. and Binder, N. 2023. ADAMTS13 activity: Screening test protocol. in: Favaloro, E. and Gosselin, R. (ed.) Hemostasis and Thrombosis: Methods and Protocols New York, NY Humana.
Lupus anticoagulant testing: Dilute prothrombin time (dPT)
Moore, G. 2023. Lupus anticoagulant testing: Dilute prothrombin time (dPT). in: Favaloro, E. and Gosselin, R. (ed.) Hemostasis and Thrombosis: Methods and Protocols New York, NY Humana.
Lupus anticoagulant testing: Taipan snake venom time with ecarin time as confirmatory test
Moore, G. 2023. Lupus anticoagulant testing: Taipan snake venom time with ecarin time as confirmatory test. in: Favaloro, E. and Gosselin, R. (ed.) Hemostasis and Thrombosis: Methods and Protocols New York, NY Humana.
ADAMTS13 antibody and inhibitor assays
Moore, G., Vetr, H. and Binder, N. 2023. ADAMTS13 antibody and inhibitor assays. in: Favaloro, E. and Gosselin, R. (ed.) Hemostasis and Thrombosis: Methods and Protocols New York, NY Humana.
Activated partial thromboplastin time and prothrombin time mixing studies: current state of the art
Adcock, D., Moore, G., Montalvão, S., Kershaw, G. and Gosselin, R. 2022. Activated partial thromboplastin time and prothrombin time mixing studies: current state of the art. Seminars in Thrombosis and Hemostasis. 49 (6), pp. 571-579. https://doi.org/10.1055/s-0042-1756196
Added value of antiphosphatidylserine/prothrombin antibodies in the workup of thrombotic antiphospholipid syndrome: Communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies
Vandevelde, A., Chayoua, W., de Laat, B., Moore, G., Musiał, J., Zuily, S., Wahl, D. and Devreese, K. 2022. Added value of antiphosphatidylserine/prothrombin antibodies in the workup of thrombotic antiphospholipid syndrome: Communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies. Journal of Thrombosis and Haemostasis. 20 (9), pp. 2136-2150. https://doi.org/10.1111/jth.15785
Effects of regional citrate anticoagulation on thrombin generation, fibrinolysis and platelet function in critically ill patients receiving continuous renal replacement therapy for acute kidney injury: a prospective study
Fisher, R., Moore, G., Mitchell, M., Dai, L., Crichton, S., Lumlertgul, N. and Ostermann, M. 2022. Effects of regional citrate anticoagulation on thrombin generation, fibrinolysis and platelet function in critically ill patients receiving continuous renal replacement therapy for acute kidney injury: a prospective study. Annals of Intensive Care. 12 (1), pp. 1-11. https://doi.org/10.1186/s13613-022-01004-w
Direct oral anticoagulants‐Remove versus Taipan snake venom time for detection of a lupus anticoagulant in patients taking oral direct factor Xa inhibitors
White, D., Moore, G., Besser, M., MacDonald, S. and Thomas, W. 2022. Direct oral anticoagulants‐Remove versus Taipan snake venom time for detection of a lupus anticoagulant in patients taking oral direct factor Xa inhibitors. Research and Practice in Thrombosis and Haemostasis. 6 (1), pp. 1-8. https://doi.org/10.1002/rth2.12648
Semiquantitative interpretation of anticardiolipin and antiβ2glycoprotein I antibodies measured with various analytical platforms: communication from the ISTH SSC subcommittee on Lupus Anticoagulant/Antiphospholipid antibodies
Vandevelde, A., Chayoua, W., de Laat, B., Gris, J., Moore, G., Musiał, J., Zuily, S., Wahl, D. and Devreese, K. 2022. Semiquantitative interpretation of anticardiolipin and antiβ2glycoprotein I antibodies measured with various analytical platforms: communication from the ISTH SSC subcommittee on Lupus Anticoagulant/Antiphospholipid antibodies. Journal of Thrombosis and Haemostasis. 20 (2), pp. 508-524. https://doi.org/10.1111/jth.15585
Snake venoms in diagnostic hemostasis and thrombosis
Moore, G. 2022. Snake venoms in diagnostic hemostasis and thrombosis. Seminars in Thrombosis and Hemostasis. 48 (02), pp. 145-160. https://doi.org/10.1055/s-0041-1732465
Applying index of circulating anticoagulant to mixing tests with lupus anticoagulant screen and confirm reagents can distinguish with high specificity between lupus anticoagulants and direct factor Xa inhibitors
Kumano, O., Amiral, J., Dunois, C., Peyrafitte, M. and Moore, G. 2021. Applying index of circulating anticoagulant to mixing tests with lupus anticoagulant screen and confirm reagents can distinguish with high specificity between lupus anticoagulants and direct factor Xa inhibitors. International Journal of Laboratory Hematology. 43 (4), pp. 771-778. https://doi.org/10.1111/ijlh.13571
Clinical validation of an automated fluorogenic factor XIII activity assay based on isopeptidase activity
Leitner, M., Büchold, C., Pasternack, R., Binder, N. and Moore, G. 2021. Clinical validation of an automated fluorogenic factor XIII activity assay based on isopeptidase activity. International Journal of Molecular Sciences. 22 (3). https://doi.org/10.3390/ijms22031002